Sunday, April 02, 2017 1:30:17 AM
chinatown1980,
Please explain Dr. Linda Liau's graph indicating that all SOC patients had evented while treatment arm patients remained without having evented. Please explain how a reportable event, such as primary completion (ie 248 PFS events and or perhaps 233 OS events) can be kept from being reported timely without legal consequences or regulator intervention to disclose it. Finally, please explain, based on your openness to the assumption of earlier 248 PFS eventing, how 233 OS events have not been timely reported based on a historical 9 month max SOC average separation between PFS events and OS events when PFS events represent 75% of enrolled patients and OS events only represents 70% of enrolled patients. Best wishes.
Please explain Dr. Linda Liau's graph indicating that all SOC patients had evented while treatment arm patients remained without having evented. Please explain how a reportable event, such as primary completion (ie 248 PFS events and or perhaps 233 OS events) can be kept from being reported timely without legal consequences or regulator intervention to disclose it. Finally, please explain, based on your openness to the assumption of earlier 248 PFS eventing, how 233 OS events have not been timely reported based on a historical 9 month max SOC average separation between PFS events and OS events when PFS events represent 75% of enrolled patients and OS events only represents 70% of enrolled patients. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
